Advertisement

Topics

BlueRock Therapeutics Wins $1M from NY State for R&D Hub, Launches MSK Neuro Collaboration

07:15 EDT 17 Apr 2018 | Genetic Engineering News

Cell-based therapy developer BlueRock Therapeutics said today it will receive $1 million from New York State for establishing a neuroscience R&D hub in New York City—a hub whose activity will include a new research collaboration with Memorial Sloan-Kettering Cancer Center (MSK), from which the company was spun out in 2016. Headquartered in Cambridge, MA, BlueRock is building out a 7800-square-foot space within the Alexandria Center for Life Science, the 728,000-square-foot Manhattan campus operated by Alexandria Real Estate Equities. The campus is located between Bellevue Hospital and NYU Medical Center. BlueRock said the location will help connect the company to top academic and medical institutions as well as major hospitals; scientific, clinical, and entrepreneurial talent; investment capital; and the city’s growing commercial life science industry. The R&D hub will be BlueRock’s third location, next to its Cambridge HQ and a research, development, and manufacturing hub within the ...

Original Article: BlueRock Therapeutics Wins $1M from NY State for R&D Hub, Launches MSK Neuro Collaboration

NEXT ARTICLE

More From BioPortfolio on "BlueRock Therapeutics Wins $1M from NY State for R&D Hub, Launches MSK Neuro Collaboration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...